Skip to main content
David Wald, MD, Pathology, Cleveland, OH, University Hospitals Cleveland Medical Center

DavidNWaldMD

Pathology Cleveland, OH

Blood Banking & Transfusion Medicine, Chemical Pathology, Anatomic Pathology, Clinical Pathology

Assistant Professor, Pathology (Clinical), Case Western Reserve University School of Medicine

Dr. Wald is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wald's full profile

Already have an account?

  • Office

    Case Western Reserve University - Wolstein Research Building
    2103 Cornell Rd WRB3-530
    Cleveland, OH 44106
    Phone+1 216-368-0945
    Fax+1 216-386-8919
  • Is this information wrong?

Education & Training

  • Case Western Reserve University/University Hospitals Cleveland Medical Center
    Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Pathology-Anatomic and Clinical, 2005 - 2008
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 2005

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2007 - 2025
  • American Board of Pathology Pathology - Clinical

Publications & Presentations

PubMed

Abstracts/Posters

  • Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer
    David Wald, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas
    David Wald, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • New Trials Following Successful Approach to Producing and Using Anti-CD19 CAR T Cells Against B-cell Malignancies
    New Trials Following Successful Approach to Producing and Using Anti-CD19 CAR T Cells Against B-cell MalignanciesDecember 21st, 2021

Hospital Affiliations